TY  - JOUR
AU  - Pérez-Valderrama, B
AU  - Arranz Arija, J A
AU  - Rodríguez Sánchez, A
AU  - Pinto Marín, A
AU  - Borrega García, P
AU  - Castellano Gaunas, D E
AU  - Rubio Romero, G
AU  - Maximiano Alonso, C
AU  - Villa Guzmán, J C
AU  - Puertas Álvarez, J L
AU  - Chirivella González, I
AU  - Méndez Vidal, M J
AU  - Juan Fita, M J
AU  - León-Mateos, L
AU  - Lázaro Quintela, M
AU  - García Domínguez, R
AU  - Jurado García, J M
AU  - Vélez de Mendizábal, E
AU  - Lambea Sorrosal, J J
AU  - García Carbonero, I
AU  - González del Alba, A
AU  - Suárez Rodríguez, C
AU  - Jiménez Gallego, P
AU  - Meana García, J A
AU  - García Marrero, R D
AU  - Gajate Borau, P
AU  - Santander Lobera, C
AU  - Molins Palau, C
AU  - López Brea, M
AU  - Fernández Parra, E M
AU  - Reig Torras, O
AU  - Basterretxea Badiola, L
AU  - Vázquez Estévez, S
AU  - González Larriba, J L
PY  - 2015
DO  - 10.1093/annonc/mdv601
UR  - http://hdl.handle.net/10668/9662
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Patients with metastatic renal carcinoma (mRCC) treated with first-line pazopanib were not included in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model. SPAZO (NCT02282579) was a nation-wide retrospective...
LA  - en
KW  - metastatic renal cell cancer
KW  - pazopanib
KW  - prognostic classification
KW  - tyrosine kinase inhibitors
KW  - Adult
KW  - Aged
KW  - Carcinoma, Renal Cell
KW  - Databases, Factual
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Indazoles
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Molecular Targeted Therapy
KW  - Prognosis
KW  - Pyrimidines
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Spain
KW  - Sulfonamides
TI  - Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
TY  - research article
VL  - 27
ER  -